Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.899 enrolled

Overview

To assess the pattern of hypertension in the population in terms of presence of additional risk factors (ARF) and cardiovascular risk stratification.

routine physician visits

Study Type

OBSERVATIONAL

Enrollment

899

Conditions

Hypertension

Interventions

Usual CareOTHER

Normal care for hypertensive patients with risk factors for CHD

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 to 80 years old * Patients with hypertension: newly diagnosed and /or already diagnosed and treated , whether at goal or not for the blood pressure level; * Patients with no history of CHD/CVD Exclusion Criteria: * None

Locations (2)

Pfizer Investigational Site

Varaždin, Croatia

Pfizer Investigational Site

Prague, Czechia

Outcomes

Primary Outcomes

Description of hypertensive patients in terms of presence of associated cardiovascular (CV) risk factors (number of additional CV risk factors and frequency)

Secondary Outcomes

Description of pattern of management of HT and CVD prevention, through lifestyle and use of drug therapies,

Estimate adherence to treatment using the Morisky Adherence Scale (MAS)

Estimation of hypertensive patients CV risk stratification based on ESH/ESC Hypertension Guidelines 2007 and to compare it with physicians' estimation of CV risk.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.